Furthermore, the ratio of GluN2A/GluN2B subunits in NMDARs has been found to be altered in rat and primate models of Parkinson’s disease and under levodopa therapy, which is associated with the development of dyskinesia14,17–19. This evidence concerns the gene GRIN2A and Parkinson disease.